KR102063554B1 - Lactobacillus gasseri swpm102 which has antifungal activity or antibacterial activity - Google Patents
Lactobacillus gasseri swpm102 which has antifungal activity or antibacterial activity Download PDFInfo
- Publication number
- KR102063554B1 KR102063554B1 KR1020180109248A KR20180109248A KR102063554B1 KR 102063554 B1 KR102063554 B1 KR 102063554B1 KR 1020180109248 A KR1020180109248 A KR 1020180109248A KR 20180109248 A KR20180109248 A KR 20180109248A KR 102063554 B1 KR102063554 B1 KR 102063554B1
- Authority
- KR
- South Korea
- Prior art keywords
- swpm102
- lactobacillus
- culture
- composition
- extract
- Prior art date
Links
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 17
- 241000186606 Lactobacillus gasseri Species 0.000 title claims abstract description 12
- 230000000843 anti-fungal effect Effects 0.000 title claims description 14
- 241000186660 Lactobacillus Species 0.000 claims description 102
- 229940039696 lactobacillus Drugs 0.000 claims description 102
- 239000000203 mixture Substances 0.000 claims description 61
- 239000000284 extract Substances 0.000 claims description 29
- 230000000845 anti-microbial effect Effects 0.000 claims description 28
- 241000894006 Bacteria Species 0.000 claims description 25
- 235000013305 food Nutrition 0.000 claims description 19
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 208000001840 Dandruff Diseases 0.000 claims description 12
- 206010016952 Food poisoning Diseases 0.000 claims description 11
- 208000019331 Foodborne disease Diseases 0.000 claims description 11
- 239000012871 anti-fungal composition Substances 0.000 claims description 11
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 10
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 10
- 239000002537 cosmetic Substances 0.000 claims description 10
- 208000002925 dental caries Diseases 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 10
- 208000032536 Pseudomonas Infections Diseases 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 241000193755 Bacillus cereus Species 0.000 claims description 6
- 241000555688 Malassezia furfur Species 0.000 claims description 6
- 241000194019 Streptococcus mutans Species 0.000 claims description 6
- 230000002062 proliferating effect Effects 0.000 claims description 6
- 208000023504 respiratory system disease Diseases 0.000 claims description 5
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 4
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 3
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 239000003613 bile acid Substances 0.000 claims description 3
- 241000245772 Gasteria Species 0.000 claims description 2
- 239000002516 radical scavenger Substances 0.000 claims 1
- 239000002609 medium Substances 0.000 description 19
- 238000011156 evaluation Methods 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- 239000011575 calcium Substances 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000003115 biocidal effect Effects 0.000 description 9
- 229910052791 calcium Inorganic materials 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 8
- 235000001465 calcium Nutrition 0.000 description 8
- 241000186869 Lactobacillus salivarius Species 0.000 description 7
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 239000004599 antimicrobial Substances 0.000 description 7
- 210000000988 bone and bone Anatomy 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 210000000689 upper leg Anatomy 0.000 description 7
- 239000011728 vitamin K2 Substances 0.000 description 7
- 235000019143 vitamin K2 Nutrition 0.000 description 7
- 241001291474 Malassezia globosa Species 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 229910052698 phosphorus Inorganic materials 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000011574 phosphorus Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 241001291477 Malassezia restricta Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 229940121375 antifungal agent Drugs 0.000 description 4
- 210000000941 bile Anatomy 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000002611 ovarian Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000555676 Malassezia Species 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- 238000002679 ablation Methods 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000003833 bile salt Substances 0.000 description 3
- 230000037118 bone strength Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 231100000676 disease causative agent Toxicity 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 208000031729 Bacteremia Diseases 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 206010014568 Empyema Diseases 0.000 description 2
- 208000001860 Eye Infections Diseases 0.000 description 2
- 206010016936 Folliculitis Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 206010031252 Osteomyelitis Diseases 0.000 description 2
- 206010033078 Otitis media Diseases 0.000 description 2
- 208000037530 Pneumonia caused by Pseudomonas aeruginosa infection Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 201000010582 ecthyma Diseases 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000011323 eye infectious disease Diseases 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 206010034674 peritonitis Diseases 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000186610 Lactobacillus sp. Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241001159568 Malassezia sp. Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical compound [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000009850 completed effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 239000005452 food preservative Substances 0.000 description 1
- 235000019249 food preservative Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002718 inhibitory effect on inflammation Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 108700029318 rat female Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C12R1/225—
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Polymers & Plastics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Physiology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Animal Husbandry (AREA)
- General Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
본 발명은 항균 활성을 갖는 락토바실러스 가세리 SWPM102 및 이를 이용한 항균 조성물, 약학적 조성물 및 식품 조성물에 대한 것이다.The present invention relates to a Lactobacillus gaseri SWPM102 having an antimicrobial activity and an antimicrobial composition, a pharmaceutical composition and a food composition using the same.
락토바실러스 속 (Lactobacillus sp.) 미생물은 동형 또는 이형발효를 하는 젖산 간균으로서 사람을 포함한 동물의 장관(Intestinal tract) 및 유제품이나 채소의 발효과정에서 흔히 볼 수 유산균의 하나이다. 락토바실러스 속 미생물은 장내 pH를 산성으로 유지시켜, 대장균(E. coli)이나 클로스트리디움(Clostridium)과 같은 유해균의 번식을 억제하고 설사와 변비를 개선할 뿐만 아니라, 비타민 합성, 항암 작용, 혈청 콜레스테롤 저하 등의 역할을 하는 것으로 알려져 있다. Lactobacillus sp. Microorganisms are lactic acid bacilli that are homozygous or heterozygous and are one of the lactic acid bacteria commonly found in the intestinal tract of animals including humans and in the fermentation of dairy products or vegetables. Lactobacillus microorganisms keep the intestinal pH acidic, inhibiting the reproduction of harmful bacteria such as E. coli and Clostridium, improving diarrhea and constipation, as well as vitamin synthesis, anticancer activity, serum It is known to play a role in lowering cholesterol.
최근에는 락토바실러스를 이용한 식품 또는 약학적 조성물들이 개발되고 있는데, 예컨대, 한국등록특허 10-1884326호는 락토바실러스 브레비스 G1(Lactobacillus brevis G1) 균주(KCCM11898P)을 포함하는 식품 알레르기 예방 및 치료용 조성물을 개시하고 있고, 한국등록특허 10-1873898호는 락토바실러스 람노서스 CJLR1505(Lactobacillus rhamnosus CJLR1505)(KCCM11721P)의 사균체를 이용한 동물 사료용 조성물을 개시하고 있다.Recently, food or pharmaceutical compositions using Lactobacillus have been developed, for example, Korean Patent No. 10-1884326 discloses a composition for preventing and treating food allergies including Lactobacillus brevis G1 strain (KCCM11898P). Korean Patent Registration No. 10-1873898 discloses a composition for animal feed using Lactobacillus rhamnosus CJLR1505 (KCCM11721P).
본 발명자들은 항균 또는 항진균 활성을 갖는 락토바실러스 속 균주에 대하여 연구하던 중 한국 임산부들의 질래 시료에서 채취한 신규 락토바실러스 가세리(Lactobacillus gasseri) SWPM102의 항균 및 항진균 활성을 확인하고 본 발명을 완성하였다.The present inventors confirmed the antibacterial and antifungal activity of the novel Lactobacillus gasseri SWPM102 collected from the samples of Korean pregnant women during the study of Lactobacillus genus strain having antibacterial or antifungal activity and completed the present invention.
본 발명의 목적은 신규 락토바실러스 가세리 균주를 제공하는 것이다.It is an object of the present invention to provide novel Lactobacillus gaseri strains.
상기 목적을 달성하기 위하여 본 발명은 항진균 또는 항균 활성을 갖는 락토바실러스 가세리(Lactobacillus gasseri) SWPM102 (기탁번호 : KCTC13437BP) 및 이를 이용한 항균 조성물, 항진균 조성물, 약학적 조성물 및 식품 조성물을 제공한다.In order to achieve the above object, the present invention provides Lactobacillus gasseri SWPM102 (Accession No .: KCTC13437BP) having antifungal or antibacterial activity and an antimicrobial composition, antifungal composition, pharmaceutical composition and food composition using the same.
본 발명의 락토바실러스 가세리 SWPM102는 항균 활성, 내담즙성, 내산성을 가지며, 항균 조성물, 항진균 조성물, 약학적 조성물 및 식품 조성물에 이용 가능하다.The Lactobacillus fern SWPM102 of the present invention has antimicrobial activity, bile resistance, and acid resistance, and can be used in antimicrobial compositions, antifungal compositions, pharmaceutical compositions, and food compositions.
도 1은 사균화된 락토바실러스 가세리 SWPM102의 전자 현미경 (SEM) 사진이다.
도 2는 락토바실러스 가세리 SWPM102 균주의 항생제 감수성 평가 결과이다.
도 3은 락토바실러스 가세리 SWPM102 균주의 억제환 측정 결과를 보여준다.
도 4는 락토바실러스 가세리 SWPM102 균주가 피부자극성이 없는 것을 보여준다.
도 5는 락토바실러스 가세리 SWPM102 균주가 염증 억제 효능을 갖는 것을 보여준다.
도 6은 락토바실러스 살리바리우스 SWPM101 및/또는 락토바실러스 가세리 SWPM102 균주를 비타민 K2와 함께 섭취 시 유의하게 체중이 증가한 것을 보여준다.1 is an electron microscopy (SEM) image of sterile Lactobacillus gasteria SWPM102.
Figure 2 shows the results of antibiotic susceptibility evaluation of Lactobacillus gaseri SWPM102 strain.
Figure 3 shows the inhibitory ring measurement results of Lactobacillus gaseri SWPM102 strain.
Figure 4 shows that the Lactobacillus gaseri SWPM102 strain is not skin irritant.
Figure 5 shows that the Lactobacillus gaseri SWPM102 strain has inhibitory effect on inflammation.
6 shows significant weight gain when ingesting Lactobacillus salivarius SWPM101 and / or Lactobacillus gaseri SWPM102 strain with vitamin K2.
본 발명은,The present invention,
항균 활성을 갖는 락토바실러스 가세리 SWPM102 (기탁번호 : KCTC13437BP)에 대한 것이다.Against Lactobacillus gaseri SWPM102 (Accession No .: KCTC13437BP) with antimicrobial activity.
또한 본 발명은 락토바실러스 가세리 SWPM102, 그 배양물 또는 그 추출물을 포함하는 항균 조성물에 대한 것이다.The present invention also relates to an antimicrobial composition comprising Lactobacillus fern SWPM102, its culture or its extract.
또한 본 발명은 락토바실러스 가세리 SWPM102, 그 배양물 또는 그 추출물을 포함하는, 식중독, 지루성 피부염, 비듬, 녹농균 감염으로 인한 호흡기 질환, 녹농균 감염으로 인한 폐렴 및 충치로 구성되는 군으로부터 선택되는 하나 이상의 질병의 예방 또는 치료용 약학적 조성물에 대한 것이다.The present invention also relates to one or more selected from the group consisting of food poisoning, seborrheic dermatitis, dandruff, respiratory disease caused by Pseudomonas aeruginosa infection, pneumonia caused by Pseudomonas aeruginosa infection, and caries, including Lactobacillus fern SWPM102, its culture or its extract It relates to a pharmaceutical composition for preventing or treating a disease.
또한 본 발명은 락토바실러스 가세리 SWPM102, 그 배양물 또는 그 추출물을 포함하는, 식중독, 지루성 피부염, 비듬, 녹농균 감염으로 인한 호흡기 질환, 녹농균 감염으로 인한 폐렴 및 충치로 구성되는 군으로부터 선택되는 하나 이상의 질병의 예방 또는 개선용 식품 조성물에 대한 것이다.The present invention also relates to one or more selected from the group consisting of food poisoning, seborrheic dermatitis, dandruff, respiratory disease caused by Pseudomonas aeruginosa infection, pneumonia caused by Pseudomonas aeruginosa infection, and caries, including Lactobacillus fern SWPM102, its culture or its extract It relates to a food composition for preventing or ameliorating diseases.
또한 본 발명은 락토바실러스 가세리 SWPM102, 그 배양물 또는 그 추출물을 포함하는, 항염증 조성물에 대한 것이다.The present invention also relates to an anti-inflammatory composition comprising Lactobacillus fern SWPM102, its culture or its extract.
이하, 본 발명을 자세히 설명한다.Hereinafter, the present invention will be described in detail.
락토바실러스 가세리 SWPM1021Lactobacillus gasserie SWPM1021
본 발명의 락토바실러스 가세리(Lactobacillusgasseri) SWPM102 (기탁번호 : KCTC 13437BP)는 항균 활성 또는 항진균 활성을 갖는다. 바람직하게는 본 발명의 락토바실러스 가세리 SWPM102은 식중독 유발균, 충치 유발균, 지루성 피부염 유발균 및 녹농균으로 구성되는 군으로부터 선택되는 하나 이상에 대하여 항균 활성 또는 항진균 활성을 갖는다. 더욱 바람직하게는 본 발명의 락토바실러스 가세리 SWPM102는 바실러스 세레우스(Bacillus cereus), 스트렙토코쿠스 뮤탄스(Streptococcus mutans), 말라세지아 퍼퍼(Malassezia furfur), 말라세지아 글로보사(Malassezia globosa), 말라세지아 레스트릭타(Malassezia restricta) 및 녹농균(Pseudomonas aeruginosa)으로 구성되는 군으로부터 선택되는 하나 이상에 대하여 항균 활성 또는 항진균 활성을 갖는다.Lactobacillus gasseri SWPM102 (Accession No .: KCTC 13437BP) of the present invention has antibacterial or antifungal activity. Preferably, the Lactobacillus gaseri SWPM102 of the present invention has antimicrobial activity or antifungal activity against at least one selected from the group consisting of food poisoning bacteria, caries causing bacteria, seborrheic dermatitis causing bacteria and Pseudomonas aeruginosa. More preferably, the Lactobacillus gaseri SWPM102 of the present invention is Bacillus cereus, Streptococcus mutans, Malassezia furfur, Malassezia globosa, Malassezia globosa, Have antimicrobial or antifungal activity against at least one selected from the group consisting of Malassezia restricta and Pseudomonas aeruginosa.
본 발명의 락토바실러스 가세리 SWPM102는 pH3 또는 pH6.8의 조건 하 증식능을 갖는다. 또한 본 발명의 락토바실러스 가세리 SWPM102는 0.3 중량% 담즙산을 포함하는 배지 조건 하 증식능을 갖는다. 이때, 증식능을 갖는다는 것은 상기 pH 조건 하 또는 담즙산 농도 조건 하, 3시간 배양 시 배양 후 생균 수가 증가하는 것을 의미한다. The Lactobacillus fern SWPM102 of the present invention has a proliferative capacity under conditions of pH 3 or pH 6.8. In addition, the Lactobacillus gaseri SWPM102 of the present invention has a proliferative capacity under medium conditions containing 0.3 wt% bile acid. In this case, having a proliferative capacity means that the number of viable cells after culturing is increased for 3 hours under the pH or bile acid concentration.
본 발명의 락토바실러스 가세리 SWPM102는 식중독을 유발하는 세균에 대한 항균 활성이 우수하다. 또한 본 발명의 가세리 SWPM102는 과산화수소 발생능을 갖는다.Lactobacillus gaseri SWPM102 of the present invention is excellent in antibacterial activity against bacteria causing food poisoning. In addition, the pod SWSW102 of the present invention has the ability to generate hydrogen peroxide.
또한 본 발명의 락토바실러스 가세리 SWPM102는 비타민과 병용 투여 시 골질환의 예방, 개선 및 치료능을 갖는다. 본 발명의 락토바실러스 가세리 SWPM102는 비타민과 병용 투여되어 비타민 K2 또는 인의 골 흡수를 촉진하며, 뼈 강도를 증가시킬 수 있다. 본 발명의 락토바실러스 가세리 SWPM102는 비타민 K2의 체내 흡수율을 증가시켜, 칼슘이 뼈에 흡수되는 것을 촉진한다. 상기 골질환은 골다공증, 골형성 부전증, 골연화증, 골량 감소증, 골절 및 골 결손으로 구성되는 군으로부터 선택될 수 있다.In addition, the Lactobacillus gaseri SWPM102 of the present invention has the ability to prevent, ameliorate and treat bone disease when administered in combination with vitamins. Lactobacillus gastrile SWPM102 of the present invention may be administered in combination with vitamins to promote bone absorption of vitamin K2 or phosphorus and increase bone strength. Lactobacillus gastrile SWPM102 of the present invention increases the absorption rate of vitamin K2 in the body, thereby promoting the absorption of calcium into bone. The bone disease may be selected from the group consisting of osteoporosis, osteoplasia, osteomalacia, osteopenia, bone loss, fractures and bone defects.
또한 락토바실러스 가세리 SWPM102는 식중독 유발 세균에 대하여 우수한 항균 활성을 나타내기 때문에 본 발명은 락토바실러스 가세리 SWPM102 균주 또는 이의 배양물을 유효성분으로 식중독 예방 및 개선을 위한 식품 보존제, 건강 보조 식품, 일반 식품, 의약외품을 제공한다.In addition, since the Lactobacillus gaseri SWPM102 shows excellent antimicrobial activity against food poisoning-inducing bacteria, the present invention is a food preservative, health supplement, general for preventing and improving food poisoning as an active ingredient of the Lactobacillus gaseri SWPM 102 strain or its culture. Provide food and quasi-drugs.
또한 락토바실러스 가세리 SWPM102는 충치 유발 세균에 대해 우수한 항균 활성을 나타내기 때문에 본 발명은 락토바실러스 가세리 SWPM102 균주 또는 이의 배양물을 유효성분으로 충치 예방 및 개선을 위한 건강 보조 식품, 일반 식품, 의약외품을 제공한다. In addition, since the Lactobacillus gaseri SWPM102 exhibits excellent antimicrobial activity against caries-causing bacteria, the present invention provides a dietary supplement, a general food, a quasi-drug for the prevention and improvement of caries using the Lactobacillus gaseri SWPM 102 strain or its culture as an active ingredient. To provide.
또한 락토바실러스 가세리 SWPM102는 비듬 유발 진균에 대해 우수한 생육 억제 활성을 나타내기 때문에 본 발명은 락토바실러스 가세리 SWPM102 균주 또는 이의 배양물을 유효성분으로 하는 지루성 피부염과 비듬 예방, 개선 또는 치료를 위한 의약품 및 의약외품, 화장품을 제공한다. 이는 두피 환경 개선을 증진시키는데 유용하다.In addition, since the Lactobacillus gaseri SWPM102 exhibits excellent growth inhibitory activity against the dandruff-inducing fungi, the present invention provides a drug for the prevention, improvement or treatment of seborrheic dermatitis and dandruff using the Lactobacillus gaseri SWPM 102 strain or its culture as an active ingredient. And quasi-drugs and cosmetics. This is useful for promoting scalp environmental improvement.
또한 락토바실러스 가세리 SWPM102는 녹농균에 대해 우수한 항균 활성을 나타낸다. 그러므로 본 발명은 락토바실러스 가세리 SWPM102 균주 또는 이의 배양물을 유효성분으로 녹농균 감염증의 예방 및 치료를 위한 의약품 등을 제공한다.In addition, Lactobacillus gaseri SWPM102 shows excellent antibacterial activity against Pseudomonas aeruginosa. Therefore, the present invention provides a drug for the prevention and treatment of Pseudomonas aeruginosa infection with Lactobacillus gaseri SWPM102 strain or its culture as an active ingredient.
항균 조성물 및 항진균 조성물Antibacterial and Antifungal Compositions
본 발명은 락토바실러스 가세리 SWPM102, 그 배양물 또는 그 추출물을 포함하는 항진균 조성물에 대한 것이다. 바람직하게는 상기 항진균 조성물은 말라세지아 퍼퍼(Malassezia furfur), 말라세지아 글로보사(Malassezia globosa) 및 말라세지아 레스트릭타(Malassezia restricta)으로 구성되는 군으로부터 선택되는 하나 이상의 진균에 대하여 항진균 활성을 갖는다.The present invention is directed to an antifungal composition comprising Lactobacillus fern SWPM102, its culture or its extract. Preferably the antifungal composition is antifungal activity against one or more fungi selected from the group consisting of Malassezia furfur, Malassezia globosa and Malassezia restricta. Has
본 발명은 락토바실러스 가세리 SWPM102, 그 배양물 또는 그 추출물을 포함하는 항균 조성물에 대한 것이다. 바람직하게는 상기 항균 조성물은 바실러스 세레우스(Bacillus cereus), 스트렙토코쿠스 뮤탄스(Streptococcus mutans) 및 녹농균(Pseudomonas aeruginosa)으로 구성되는 군으로부터 선택되는 하나 이상의 세균에 대하여 항균 활성을 갖는다. The present invention is directed to an antimicrobial composition comprising Lactobacillus fern SWPM102, its culture or its extract. Preferably, the antimicrobial composition has antimicrobial activity against at least one bacterium selected from the group consisting of Bacillus cereus, Streptococcus mutans, and Pseudomonas aeruginosa.
“항균” 또는 “항진균”은 특정 농도에서 미생물의 성장 또는 생존을 감소, 방지, 억제, 또는 제거하는 능력을 의미한다. 항균용 조성물 또는 항진균 조성물이란 항미생물제를 총칭하는 의미인 항생제와 같은 의미일 수 있고, 항균제, 살균제, 방부제, 보존제 또는 제균제와 같은 의미일 수 있으며, 바람직하게는 그람양성균, 그람음성균, 진균 (효모 및 곰팡이)으로 이루어진 군에서 선택된 1 종 이상의 미생물의 발육과 생활 기능을 저지 또는 억제할 수 있는 물질 즉, 항세균 및 항진균 효력이 있는 물질을 의미한다."Antibacterial" or "antifungal" means the ability to reduce, prevent, inhibit, or eliminate the growth or survival of microorganisms at certain concentrations. The antimicrobial composition or the antifungal composition may mean the same as an antibiotic which is a generic term for an antimicrobial agent, and may mean the same as an antimicrobial agent, a fungicide, a preservative, a preservative or an antifungal agent, and preferably, Gram-positive bacteria, Gram-negative bacteria, fungi ( Yeast and fungus) means a substance capable of inhibiting or inhibiting the development and life function of at least one microorganism selected from the group consisting of substances, that is, antibacterial and antifungal substances.
본 발명의 항균 또는 항진균 조성물은, 식중독 예방은 식품에 첨가하거나 식품과 별도로 투여하거나 이때 적절한 형태의 조성물로 제조하여 투여할 수 있다. 상기와 같은 측면에서, 상기 항균 또는 항진균 조성물은, 건강 보조 식품, 의약품, 의약외품, 화장품 형태일 수 있다. 본 발명의 항균 또는 항진균 조성물은, 충치 예방은 입 안에서 씹거나 씹어서 삼키거나 가글할 수 있는 형태의 조성물로 제조하여 투여할 수 있다. 상기와 같은 측면에서, 상기 조성물은, 건강 보조 식품, 일반 식품, 의약외품의 형태일 수 있다. 본 발명의 항균 또는 항진균 조성물은, 지루성 피부염, 지루성 두피염 또는 비듬의 예방, 개선 또는 치료용 조성물일 수 있다. 구체적으로, 말라세지아 퍼퍼, 말라세지아 글로보사 및 말라세지아 레스트릭타는 지루성 피부염, 지루성 두피염 및 비듬을 유발하는 것으로 알려져 있으므로, 상기 균들의 증식, 생장을 억제하거나 상기 균들을 사멸시켜 지루성 피부염, 지루성 두피염 및 비듬의 예방, 개선 또는 치료 효과를 기대할 수 있다. 상기와 같은 측면에서, 상기 조성물은, 의약품, 의약외품, 화장품의 형태일 수 있다Antimicrobial or antifungal composition of the present invention, food poisoning prevention may be added to food or administered separately from the food, or at this time prepared and administered in a composition of the appropriate form. In the above aspect, the antimicrobial or antifungal composition may be in the form of dietary supplements, medicines, quasi-drugs, cosmetics. The antimicrobial or antifungal composition of the present invention may be administered in the form of a composition that can prevent tooth decay, chew, chew, swallow or gargle. In the above aspects, the composition may be in the form of dietary supplements, general foods, quasi-drugs. The antimicrobial or antifungal composition of the present invention may be a composition for preventing, improving or treating seborrheic dermatitis, seborrheic scalpitis or dandruff. Specifically, Malassezia puffer, Malassezia globosa, and Malassezia restricta are known to cause seborrheic dermatitis, seborrheic scalpitis, and dandruff, thus inhibiting the growth and growth of the bacteria or killing the bacteria, which is seborrheic. The effect of preventing, improving or treating dermatitis, seborrheic scalitis and dandruff can be expected. In the above aspects, the composition may be in the form of medicines, quasi-drugs, cosmetics.
약학적 조성물Pharmaceutical composition
본 발명은 락토바실러스 가세리 SWPM102, 그 배양물 또는 그 추출물을 포함하는 약학적 조성물에 대한 것이다. 바람직하게는 본 발명은 락토바실러스 가세리 SWPM102, 그 배양물 또는 그 추출물을 포함하는, 식중독, 지루성 피부염, 비듬, 녹농균 감염으로 인한 질병 및 충치로 구성되는 군으로부터 선택되는 하나 이상의 질병의 예방 또는 치료용 약학적 조성물에 대한 것이다. 녹농균에 의한 감염성 질병은 호흡기 질환, 패혈증, 전신감염, 기도감염, 낭포성 섬유증, 녹농균 모낭염, 골수염, 괴저성 농창(ecthyma gangraenosum), 방광염, 중이염, 농흉(empyema), 폐렴, 뇌막염, 복막염, 각막염, 내안구염 및 균혈증을 포함하나 이에 본 발명이 제한되는 것은 아니고, 녹농균에 의하여 발생할 수 있는 이차감염을 모두 포함한다.The present invention relates to a pharmaceutical composition comprising the Lactobacillus fern SWPM102, its culture or its extract. Preferably the present invention provides for the prevention or treatment of at least one disease selected from the group consisting of Lactobacillus gaseri SWPM102, its culture or its extracts, the group consisting of food poisoning, seborrheic dermatitis, dandruff, diseases caused by Pseudomonas aeruginosa infection and caries. For pharmaceutical compositions. Infectious diseases caused by Pseudomonas aeruginosa include respiratory disease, sepsis, systemic infection, airway infection, cystic fibrosis, Pseudomonas aeruginosa folliculitis, osteomyelitis, ecthyma gangraenosum, cystitis, otitis media, empyema, pneumonia, meningitis, peritonitis, keratitis Including, but not limited to the present invention, such as eye infections and bacteremia, and includes all secondary infections that can be caused by Pseudomonas aeruginosa.
본 발명의 항균용 조성물의 투여량은 투여 대상에서 상기 유해 세균을 사멸시키는 효과를 발휘하기 위해 요구되는 정도의 양을 의미하는데, 제형의 종류 및 투여 대상의 연령, 체중, 일반 건강 상태, 성별 및 식이, 투여 경로, 투여 시간 및 기간을 비롯한 다양한 인자에 따라 조절될 수 있다. 락토바실러스 가세리 SWPM102 균주, 그 파쇄물, 그 배양액 또는 그 추출물은, 조성물 총 중량을 기준으로, 0.01중량% 내지 10중량%로 포함될 수 있다. 일 구체예에서, 상기 락토바실러스 가세리 SWPM102 균주, 그 파쇄물, 그 배양액 또는 그 추출물은, 조성물 총 중량을 기준으로, 0.1중량%~5중량%로 포함될 수 있다. 상기와 같은 측면에서, 락토바실러스 가세리 SWPM102 균주, 그 파쇄물, 그 배양액 또는 그 추출물은, 조성물 총 중량을 기준으로, 0.01중량% 이하로도 포함될 수 있다.Dosage of the antimicrobial composition of the present invention means the amount required to exert the effect of killing the harmful bacteria in the subject, the type of formulation and the age, weight, general state of health, sex and It may be adjusted according to various factors including the diet, the route of administration, the time of administration, and the duration of administration. Lactobacillus gaseri SWPM102 strain, its lysate, its culture or its extract may be included in an amount of 0.01% to 10% by weight based on the total weight of the composition. In one embodiment, the Lactobacillus gaseri SWPM102 strain, its lysate, its culture or its extract may be included in an amount of 0.1% to 5% by weight based on the total weight of the composition. In this aspect, the Lactobacillus gaseri SWPM102 strain, its lysate, its culture or its extract may be included in an amount of 0.01% by weight or less based on the total weight of the composition.
상기 약학적 조성물은 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다. 상기 약학적 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 본 발명에 따른 상기 약학조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유 등을 포함한 다양한 화합물 혹은 혼합물을 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 추출물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로젤라틴 등이 사용될 수 있다.The pharmaceutical composition may further comprise suitable carriers, excipients and diluents commonly used in the manufacture. The pharmaceutical composition may be used in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral formulations, external preparations, suppositories, and sterile injectable solutions, respectively, according to conventional methods. . Carriers, excipients and diluents which may be included in the pharmaceutical composition according to the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, Various compounds or mixtures, including calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like. . When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and the solid preparations may include at least one excipient such as starch, calcium carbonate, sucrose in the extract. ) Or lactose, gelatin and the like are mixed. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
식품 조성물Food composition
본 발명은 락토바실러스 가세리 SWPM102, 그 배양물 또는 그 추출물을 포함하는 식품 조성물에 대한 것이다. 바람직하게는 본 발명은 락토바실러스 가세리 SWPM102, 그 배양물 또는 그 추출물을 포함하는, 식중독, 지루성 피부염, 비듬, 녹농균 감염으로 인한 질병 및 충치로 구성되는 군으로부터 선택되는 하나 이상의 질병의 예방 또는 개선용 식품 조성물에 대한 것이다. 녹농균에 의한 감염성 질병은 호흡기 질환, 패혈증, 전신감염, 기도감염, 낭포성 섬유증, 녹농균 모낭염, 골수염, 괴저성 농창(ecthyma gangraenosum), 방광염, 중이염, 농흉(empyema), 폐렴, 뇌막염, 복막염, 각막염, 내안구염 및 균혈증을 포함하나 이에 본 발명이 제한되는 것은 아니고, 녹농균에 의하여 발생할 수 있는 이차감염을 모두 포함한다. The present invention relates to a food composition comprising the Lactobacillus fern SWPM102, its culture or its extract. Preferably the present invention provides for the prevention or amelioration of one or more diseases selected from the group consisting of Lactobacillus gaseri SWPM102, its culture or its extract, and diseases caused by food poisoning, seborrheic dermatitis, dandruff, Pseudomonas aeruginosa infection and caries. For food compositions. Infectious diseases caused by Pseudomonas aeruginosa include respiratory disease, sepsis, systemic infection, airway infection, cystic fibrosis, Pseudomonas aeruginosa folliculitis, osteomyelitis, ecthyma gangraenosum, cystitis, otitis media, empyema, pneumonia, meningitis, peritonitis, keratitis Including, but not limited to the present invention, such as eye infections and bacteremia, and includes all secondary infections that can be caused by Pseudomonas aeruginosa.
상기 식품 조성물은 건강 식품 조성물일 수 있으며, 식품 조성물의 제형은 특별히 한정되지 않으나, 예를 들어, 정제, 환제, 연질 및 경질 캅셀제, 과립제, 드링크제, 캐러멜, 분말 등으로 제형화 될 수 있다. 각 제형의 식품 조성물은 유효 성분 이외에 해당 분야에서 통상적으로 사용되는 성분들을 제형 또는 사용 목적에 따라 당업자가 어려움 없이 적의 선정하여 배합할 수 있으며, 다른 원료와 동시에 적용할 경우 상승 효과가 일어날 수 있다. 상기 유효 성분의 투여량 결정은 당업자의 수준 내에 있으며, 이의 1일 투여 용량은 예를 들어 락토바실러스 가세리가 105 내지 1013 CFU/일, 보다 구체적으로는 108내지 1010 CFU/일이 될 수 있으나, 이에 제한되지 않으며, 투여하고자 하는 대상의 연령, 건강 상태, 합병증 등의 다양한 요인에 따라 달라질 수 있다.The food composition may be a health food composition, the formulation of the food composition is not particularly limited, for example, it may be formulated into tablets, pills, soft and hard capsules, granules, drinks, caramels, powders and the like. In addition to the active ingredient, the food composition of each formulation may be suitably selected by those skilled in the art according to the formulation or purpose of use in addition to the active ingredient, and may be combined with other raw materials, and synergistic effects may occur when applied simultaneously with other raw materials. Determination of the dosage of the active ingredient is within the level of those skilled in the art, and its daily dosage will be, for example, from 10 5 to 10 13 CFU / day, more specifically from 10 8 to 10 10 CFU / day. However, the present invention is not limited thereto and may vary depending on various factors such as age, health condition, complications, etc. of the target subject to be administered.
항염증 조성물Anti-inflammatory composition
본 발명은 락토바실러스 가세리 SWPM102, 그 배양물 또는 그 추출물을 포함하는, 항염증 조성물에 대한 것이다.The present invention is directed to an anti-inflammatory composition comprising Lactobacillus fern SWPM102, its culture or its extract.
항균용 미생물 제제의 제조 방법Manufacturing method of antimicrobial preparations for antibacterial
본 발명은 락토바실러스 가세리 SWPM102 균주를 배양하는 단계를 포함하는 항균용 미생물 제제의 제조 방법에 대한 것이다.The present invention relates to a method for producing an antimicrobial microbial agent comprising the step of culturing the Lactobacillus gaseri SWPM102 strain.
화장료 조성물Cosmetic composition
본 발명은 락토바실러스 가세리 SWPM102, 그 배양물 또는 그 추출물을 포함하는, 화장료 조성물에 대한 것이다. 상기 화장료 조성물은 모든 제형으로 제공될 수 있다. 예를 들면, 액상, 에멀젼, 현탁액, 고체, 겔, 분말, 페이스트, 폼 에어로졸 또는 패치 조성물의 제형으로 제공될 수 있다. 이러한 제형의 조성물은 당해 분야의 통상적인 방법에 따라 제조될 수 있다.The present invention relates to a cosmetic composition comprising the Lactobacillus fern SWPM102, its culture or its extract. The cosmetic composition may be provided in any formulation. For example, it may be provided in the form of a liquid, emulsion, suspension, solid, gel, powder, paste, foam aerosol or patch composition. Compositions of such formulations may be prepared according to conventional methods in the art.
상기 화장료 조성물은 상기한 물질 이외에 주 효과를 손상시키지 않는 범위 내에서, 바람직하게는 주 효과에 상승 효과를 줄 수 있는 다른 성분들을 함유할 수 있다. 본 발명에 따른 화장료 조성물은 비타민, 아미노산, 고분자 펩타이드, 지질로 이루어진 군에서 선택된 물질을 포함할 수 있다. 또한 본 발명에 따른 화장료 조성물은 보습제, 에몰리언트제, 계면 활성제, 자외선 흡수제, 방부제, 살균제, 산화 방지제, pH 조정제, 유기 및 무기 안료, 향료를 포함할 수 있다. 상기 성분의 배합량은 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 당업자가 용이하게 선정 가능하며, 그 배합량은 조성물 전체 중량을 기준으로 0.01~5 중량%, 구체적으로 0.01~3 중량%일 수 있다.The cosmetic composition may contain, in addition to the above-mentioned materials, other ingredients that can give a synergistic effect to the main effect within a range that does not impair the main effect. Cosmetic composition according to the present invention may include a substance selected from the group consisting of vitamins, amino acids, polymer peptides, lipids. In addition, the cosmetic composition according to the present invention may include a moisturizer, an emulsifier, a surfactant, a ultraviolet absorbent, a preservative, a bactericide, an antioxidant, a pH adjuster, organic and inorganic pigments, and a fragrance. The blending amount of the above components can be easily selected by those skilled in the art within the range that does not impair the object and effect of the present invention, the blending amount may be 0.01 to 5% by weight, specifically 0.01 to 3% by weight based on the total weight of the composition. have.
사료 조성물Feed composition
본 발명은 락토바실러스 가세리 SWPM102, 그 배양물 또는 그 추출물을 포함하는, 사료 조성물에 대한 것이다.The present invention relates to a feed composition comprising the Lactobacillus fern SWPM102, its culture or its extract.
본 발명의 조성물Compositions of the Invention
본 발명은 락토바실러스 가세리 SWPM102, 그 배양물 또는 그 추출물을 포함하는 조성물에 대한 것이다. 이 때, 상기 배양물 또는 추출물은 락토바실러스 가세리 SWPM102 균주의 생균 또는 사균, 상기 균주의 파쇄물, 상기 균주의 배양물, 상기 배양물의 농축액, 상기 배양물의 건조물 및 상기 배양물의 추출물 등을 포함한다. 상기 사균은 본 발명의 락토바실러스 가세리 SWPM102를 배양한 후 가열, 냉각 등의 온도, 초음파, 효소, 압력, 산 및 염기 등의 처리를 통해 생균을 사멸시킨 사균으로서, 균주의 발효에 의한 대사산물을 포함하는 배양액을 포함하거나 포함하지 않을 수 있다. 발효에 의한 배양액을 포함 시키지 않을 경우 발효시킨 배양액을 여과 또는 원심 분리하여 균체를 회수한 후 생균을 사멸시키거나, 먼저 사멸시킨 후 배양액으로부터 사멸된 균체를 회수할 수도 있다. 본 발명의 균주를 배양하는 방법은 당업계에 통상적으로 이용되는 방법에 따라 배양할 수 있다. 상기 균주 배양물의 추출물은 균주 배양물의 용매 추출물이 수 있다. 상기 용매는 당업계에서 일반적으로 사용하는 용매이면 되고, 특별히 제한되지 않는다. 예컨대, 상기 용매는 에틸 아세테이트일 수 있다. 상기 배양물은 락토바실러스 가세리 SWPM102 균주를 배양 배지 또는 배양액에서 배양한 것을 의미하며, 상기 배양물은 본 발명의 균주를 포함하거나 포함하지 않을 수 있다. 상기 배양물은 그 제형이 액체 또는 고체일 수 있으나, 이에 제한되는 것은 아니다.The present invention relates to a composition comprising the Lactobacillus fern SWPM102, its culture or its extract. At this time, the culture or extract includes live or dead bacteria of Lactobacillus gaseri SWPM102 strain, crushed product of the strain, culture of the strain, concentrate of the culture, dried product of the culture, extract of the culture, and the like. The bacterium is a bacterium that killed live bacteria by incubating the Lactobacillus gaseri SWPM102 of the present invention through treatment of heating, cooling, temperature, ultrasonic wave, enzyme, pressure, acid, and base, and the like. It may or may not include a culture solution comprising a. When the culture medium by fermentation is not included, the fermented culture solution may be filtered or centrifuged to recover the cells and then the live cells are killed, or the first cells may be killed and then the killed cells may be recovered from the culture solution. The method of culturing the strain of the present invention may be cultured according to methods commonly used in the art. The extract of the strain culture may be a solvent extract of the strain culture. The solvent may be any solvent generally used in the art, and is not particularly limited. For example, the solvent may be ethyl acetate. The culture means that the Lactobacillus gaseri SWPM102 strain is cultured in the culture medium or the culture medium, the culture may or may not include the strain of the present invention. The culture may be a liquid or a solid, but the formulation is not limited thereto.
본 발명의 이점 및 특징, 그리고 그것들을 달성하는 방법은 상세하게 후술되어 있는 실시예들을 참조하면 명확해질 것이다. 그러나, 본 발명은 이하에서 개시되는 실시예들에 한정되는 것이 아니라 서로 다른 다양한 형태로 구현될 것이며, 단지 본 실시예들은 본 발명의 개시가 완전하도록 하며, 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 발명의 범주를 완전하게 알려주기 위해 제공되는 것이며, 본 발명은 청구항의 범주에 의해 정의될 뿐이다.Advantages and features of the present invention and methods for achieving them will be apparent with reference to the embodiments described below in detail. However, the present invention is not limited to the embodiments disclosed below, but may be implemented in various different forms, only the present embodiments to make the disclosure of the present invention complete, and common knowledge in the art to which the present invention pertains. It is provided to fully inform the person having the scope of the invention, which is defined only by the scope of the claims.
<재료 및 방법><Materials and Methods>
비교 균주로는 락토바실러스 가세리 (Lactobacillus gasseri strain ATCC 33323 NR_075051.1)를 구입하여 사용하였다. 또한 본 발명자가 보유하고 있던 락토바실러스 살리바리우스 SWPM101 (KCTC13436BP)를 사용하였다.As a comparative strain, Lactobacillus gasseri strain ATCC 33323 NR_075051.1 was purchased and used. In addition, the present inventors used Lactobacillus salivarius SWPM101 (KCTC13436BP).
<실험예 1> 미생물 락토바실러스 가세리 SWPM102 균주의 분리 및 동정Experimental Example 1 Isolation and Identification of Microbial Lactobacillus Gaseri SWPM102 Strains
건양대병원 산부인과에 정기검진을 받기 위해 내원한 건강한 한국인 임산부들의 동의를 받아 이들 임산부들의 질내 시료를 채취하였다. 상기 시료로부터 분리된 균주를 1.5% 한천(agar)이 포함된 MRS 고체 배지 (Difco, USA)에 도말하여 37℃에서 48시간, GasPak (BD, USA)을 이용해 혐기 조건에서 배양하였다. 순수 분리된 집락을 백금이(loop)로 취하여 MRS 액체 배지(Difco, USA)에서 37℃, 48시간, 혐기배양 하였다.Intravaginal samples were collected with the consent of healthy Korean pregnant women who visited the Department of Obstetrics and Gynecology at Konyang University Hospital. Strains isolated from the sample were plated in MRS solid medium containing 1.5% agar (Difco, USA) and incubated in anaerobic conditions using GasPak (BD, USA) for 48 hours at 37 ℃. Purely isolated colonies were taken as platinum loops and were anaerobicly cultured at 37 ° C. for 48 hours in MRS liquid medium (Difco, USA).
그런 다음, 배양된 균주의 동정 및 분류를 위하여 16s rRNA 유전자 염기서열 및 Miseq을 이용하여 초안 유전체 정보를 분석하였다. 상기 균주의 16s rRNA 유전자의 염기서열 결정(서열번호 1) 및 분석 결과는 표 1과 같다. 16s rRNA 염기서열 분석 결과, 상기 균주는 락토바실러스 가세리 (Lactobacillus gasseri strain ATCC 33323 NR_075051.1)와 가장 높은 상동성(99%)을 나타내어 락토바실러스 가세리(Lactobacillus gasseri)로 동정하였다. 상기 균주를 락토바실러스 가세리 SWPM102로 명명하였으며, 생명공학연구원 유전자은행에 2017년 12월 15일자로 기탁하였다 (수탁번호 KCTC13437BP).Then, the draft genome information was analyzed using 16s rRNA gene sequence and Miseq for identification and classification of cultured strains. Nucleotide sequence determination (SEQ ID NO: 1) and analysis results of the 16s rRNA gene of the strain are shown in Table 1. As a result of 16s rRNA sequencing, the strain exhibited the highest homology (99%) with Lactobacillus gasseri strain (Lactobacillus gasseri strain ATCC 33323 NR_075051.1) and was identified as Lactobacillus gasseri. The strain was named Lactobacillus gaseri SWPM102 and was deposited on December 15, 2017 by the Biotechnology Research Institute Gene Bank (Accession Number KCTC13437BP).
상기 락토바실러스 가세리 SWPM102 균주를 배양하여 70 ℃에서 2시간 동안 틴딜화(tyndallization)하여 균주를 사균화시킨 후, 사균화된 균주의 형태를 전자현미경(SEM)으로 사진 촬영하였다(도 1).After culturing the Lactobacillus gaseri SWPM102 strain and tyndallization (tyndallization) for 2 hours at 70 ℃, the morphized strain was photographed by electron microscopy (SEM) (Fig. 1).
<실험예 2> 내산성 평가Experimental Example 2 Acid Resistance Evaluation
락토바실러스 가세리 SWPM102 균주의 내산성을 평가하였다. 이때 비교 균주로는 락토바실러스 가세리 ATCC 33323 균주를 사용하였다. 평가 방법은 하기와 같다. 균주들을 MRS 액체 배지(pH 6.8)를 pH 2와 pH 3으로 적정하여 만든 산성 액체 배지에서 10-6 배율로 희석하였다. 희석한 균액을 100uL씩 도말하여 24시간 동안 37℃에서 혐기 배양한 뒤 콜로니 수를 측정하면서 시간대별로 MRS agar 배지에 도말하여 48시간 동안 혐기적으로 배양한 후 콜로니 수를 측정하였다. Acid resistance of the Lactobacillus gaseri SWPM102 strain was evaluated. At this time, the Lactobacillus gasery ATCC 33323 strain was used as a comparative strain. The evaluation method is as follows. Strains were diluted at 10 −6 magnification in acidic liquid medium prepared by titrating MRS liquid medium (pH 6.8) to pH 2 and pH 3. After diluting the diluted bacteria solution by 100uL and anaerobic incubation at 37 ℃ for 24 hours, the number of colonies was smeared in MRS agar medium for each time period while incubating anaerobicly for 48 hours and the number of colonies was measured.
그 결과, 락토바실러스 가세리 SWPM102 균주는 pH 3의 배양 조건에서 성장하는 것이 관찰되어, 내산성을 가지고 있는 것이 확인되었다(표 2).As a result, it was observed that the Lactobacillus gaseri SWPM102 strain was grown under culture conditions of pH 3, and it was confirmed that it had acid resistance (Table 2).
<실험예 3> 내담즙성 평가Experimental Example 3 Evaluation of Bile Resistance
락토바실러스 가세리 SWPM102 균주의 내산성을 평가하였다. 이때 비교 균주로는 락토바실러스 가세리 ATCC 33323 균주를 사용하였다. 평가 방법은 하기와 같다. 0.3 중량%, 1 중량 %의 담즙산염이 포함된 배지에 균주를 37℃, 24시간 혐기 배양하면서 MRS agar 배지에 도말하여 48시간 동안 혐기 배양한 후 콜로니 수를 측정하였다. Acid resistance of the Lactobacillus gaseri SWPM102 strain was evaluated. At this time, the Lactobacillus gasery ATCC 33323 strain was used as a comparative strain. The evaluation method is as follows. Colonies were measured after anaerobic incubation for 48 hours by smearing the strain in a medium containing 0.3% by weight, 1% by weight bile salt at 37 ℃, 24 hours anaerobic culture.
그 결과, 락토바실러스 가세리 SWPM102 균주는 0.3 중량% 담즙산염 농도에서, 우수한 성장력을 보였으며, 1 중량%의 담즙산염 농도에서도 큰 저항성을 나타내었다. 0.3 중량% 농도의 담즙농도는 사람 소장 내 평균 담즙 농도이므로 락토바실러스 가세리 SWPM102 균주를 경구 섭취하는 경우에도 상기 균주는 높은 생존율을 유지할 것으로 판단되었다 (표 3).As a result, Lactobacillus gaseri SWPM102 strain showed excellent growth ability at 0.3 wt% bile salt concentration, and showed great resistance even at 1 wt% bile salt concentration. Since the bile concentration of 0.3% by weight is the average bile concentration in the human small intestine, the strain was determined to maintain a high survival rate even when orally ingested Lactobacillus gaseri SWPM102 strain (Table 3).
<실험예 4> 균주의 과산화수소 생성활성Experimental Example 4 Hydrogen Peroxide Production Activity of Strains
과산화수소 생성 정도를 평가하기 위하여 MRS-TMB 고체 배지를 하기 표 4와 같이 제조하였다. 락토바실러스 가세리 SWPM102 균주, 락토바실러스 살리바리우스 SWPM101, 락토바실러스 가세리 SWPM101 균주들을 각각 MRS 액상 배지를 사용하여 37℃에서 48시간 배양한 다음 MRS-TMB 고체 배지에 접종한 후 48시간 37℃에서 혐기 배양하였다. 배양 후 배지를 공기 중에 30분간 노출시키고 균락이 푸른색으로 변화하는 정도를 육안으로 관찰하였다. 이때 변색이 되지 않으면 변색이 되지 않으면 (-), 일부 콜로니만 변색이 되면 (+), 전체적으로 변색 되었으나 색이 옅으면 (++), 콜로니가 진한 푸른색을 나타내면 3급 (+++)으로 등급을 분류하였다.MRS-TMB solid medium was prepared as shown in Table 4 below to evaluate the degree of hydrogen peroxide production. Lactobacillus gaseri SWPM102 strain, Lactobacillus salivarius SWPM101, and Lactobacillus gaseri SWPM101 strains were incubated for 48 hours at 37 ° C. using MRS liquid medium, and then inoculated in MRS-TMB solid medium for 48 hours at 37 ° C. Incubated. After incubation, the medium was exposed to air for 30 minutes, and the extent to which the cracks turned blue was visually observed. If it does not change color (-), if only some colonies are discolored (+), the whole color is discolored, but if the color is light (++), if the colony shows a dark blue color, it is 3rd grade (+++) Classifieds were classified.
그 결과, 락토바실러스 가세리 SWPM102는 과산화수소 생성력 있음을 확인하였다(표 5).As a result, it was confirmed that the Lactobacillus fern SWPM102 had the ability to generate hydrogen peroxide (Table 5).
<실험예 5> 항생제 감수성 평가Experimental Example 5 Evaluation of Antibiotic Susceptibility
기능성 식품 소재 등으로 활용시의 안전성을 확인하기 위하여 락토바실러스 가세리 SWPM102 균주에 대하여 항생제 저항성을 평가하였다. 현재 락토바실러스 계열 유산균의 식품 활용시의 항생제 저항성에 관한 규격기준은 설정되어 있지 않는 바, 동물성 사료에 첨가되는 미생물의 항생제 저항성에 관한 국제 기준인 EFSA 기준을 바탕으로 평가하였다.Antimicrobial resistance was evaluated against the Lactobacillus gaseri SWPM102 strain to confirm its safety when used as a functional food material. At present, there are no standard criteria for antibiotic resistance of Lactobacillus-based lactobacillus in food application, and the evaluation is based on the EFSA standard, which is an international standard for antibiotic resistance of microorganisms added to animal feed.
구체적으로, 락토바실러스 가세리 SWPM102 균주의 항생제 감수성 평가는 국제 기준인 EFSA (European Food Safety Authority) 지침에 의거하여, ampicillin (AMP), chloramphenicol (CHR), clindamycin(CLM), erythromycin (ERY), gentamycin (GEN), streptomycin (STR), tetracylcine (TET), vancomycin(VAN) 등 8종의 항생제를 대상으로 실시하였다. 항생제 저항성 평가 시에 사용된 시험방법은 유산균의 항생제 저항성 시험을 위한 SOP 기준으로 실시하였고, LSM-Broth에 ~6 x 106 CFU/ml로 락토바실러스 가세리 SWPM102 균주를 접종한 후, 각 항생제 별 MIC test strip을 올려놓고 37℃에서 48시간 동안 혐기배양 후 억제 정도 및 MIC를 평가하였다.Specifically, antibiotic susceptibility evaluation of the Lactobacillus gaseri SWPM102 strain is based on the International Standard for Food Safety Authority (EFSA), ampicillin (AMP), chloramphenicol (CHR), clindamycin (CLM), erythromycin (ERY), gentamycin Eight antibiotics (GEN), streptomycin (STR), tetracylcine (TET) and vancomycin (VAN) were tested. The test method used for antibiotic resistance evaluation was conducted as an SOP standard for antibiotic resistance test of lactic acid bacteria. After inoculating LSM-Broth with Lactobacillus gaseri SWPM102 strain at ~ 6 x 10 6 CFU / ml, The MIC test strip was placed and the degree of inhibition and MIC were evaluated after anaerobic culture for 48 hours at 37 ° C.
그 결과, 락토바실러스 가세리 SWPM102 균주는 사용된 8종의 항생제에 대하여 모두 EFSA의 기준(표 4의 EFSA guideline)을 만족하는 항생제 감수성을 나타내었는바, 경구 섭취를 통한 건강 보조 식품으로서의 활용 가능성이 기대되었다(표 6, 도 2).As a result, the Lactobacillus gaseri SWPM102 strain showed antibiotic susceptibility to all eight antibiotics used that met the EFSA standard (EFSA guideline in Table 4). Expected (Table 6, Figure 2).
<실험예 6> 항균력 평가Experimental Example 6 Evaluation of Antibacterial Activity
락토바실러스 가세리 SWPM102 균주의 배양액의 항균력을 측정하기 위하여 KS 항균력 시험방법을 사용하여 평가하였다. 평가 방법은 하기와 같다. 바실러스 세레우스(Bacillus cereus), 스트렙토코쿠스 뮤탄스(Streptococcus mutans), 말라세지아(Malassezia sp.)로 구체적으로 말라세지아 퍼퍼(Malassezia furfur), 말라세지아 글로보사(Malassezia globosa) 및 말라세지아 레스트릭타(Malassezia restricta), 녹농균(Pseudomonas aeruginosa) 배양액을 1.0mL씩 채취하여 250mL 용량의 멸균 삼각 플라스크에 접종하여 (37±1) ℃에서 24시간 진탕 배양하였다. 배양 용액의 균수를 흡광 강도계로 측정하여 추정한 후 희석 용액은 TSB배지에서 균 수가 1-5 x 105 개 (CFU/mL)가 되도록 희석 조제하여 사용하였다. 시료를 가로 세로 각각 1.0cm x 1.0cm 크기로 준비하고 70% 에탄올로 살균하여 (105±1)℃의 건조기에서 30분간 건조하거나 자외선 (UV254nm)살균기에서 2시간 이상 살균하여 사용하였다. 한편, 시험 시료와 동일한 크기 또는 양으로 균들을 채취하여 항균 가공 시험 시료와 동일하게 처리한 검체를 준비하고, 이것을 대조 시료로 사용하였다. 미리 조정하여 둔 각각의 시험 용액에 시험 시료와 대조 시료를 넣고 균 배양액을 1.0mL씩 접종하여 균일하게 혼합하고 접종 즉시 시험 시료와 대조 시료를 포함하고 있는 삼각 플라스크로부터 균 약을 일정량 채취하여 생리 식염수로 희석하고, TSA 배지를 사용하여 (37±1)℃에서 24시간 배양 후 균수를 확인하였다. 이때 희석 비율은 101 내지 104의 희석 범위로 하였다. 시험 시료에 의한 세균의 감소율은 하기 식 1에 따라 계산하였다.In order to measure the antimicrobial activity of the culture medium of Lactobacillus gaseri SWPM102 strain was evaluated using the KS antimicrobial test method. The evaluation method is as follows. Bacillus cereus, Streptococcus mutans, Malassezia (Malassezia sp.), Specifically Malassezia furfur, Malassezia globosa and Malassezia globosa. 1.0 ml of M. malassezia restricta and Pseudomonas aeruginosa cultures were harvested and inoculated into a 250 mL sterile Erlenmeyer flask and shaken at 37 ° C. for 24 hours. After estimating the bacterial count of the culture solution by measuring the absorbance intensity meter, the diluted solution was diluted and prepared so that the bacterial count was 1-5 x 10 5 (CFU / mL) in TSB medium. Samples were prepared in a size of 1.0 cm x 1.0 cm, respectively, sterilized with 70% ethanol and dried for 30 minutes in a dryer (105 ± 1) ℃ or sterilized for 2 hours or more in an ultraviolet (UV254nm) sterilizer. On the other hand, by collecting the bacteria in the same size or amount as the test sample, a sample prepared in the same manner as the antimicrobial processing test sample was prepared, and used as a control sample. Put the test sample and the control sample into each test solution prepared in advance, and inoculate 1.0 mL of the bacterial culture solution and mix it uniformly. After diluting with, and incubating for 24 hours at (37 ± 1) ℃ using TSA medium was confirmed the number of bacteria. At this time, the dilution ratio was in the dilution range of 10 1 to 10 4 . The reduction rate of bacteria by the test sample was calculated according to the following formula (1).
<식 1><Equation 1>
이때,At this time,
Mb: 24시간 배양 후 대조 시료의 균수 (평균값)Mb: Number of bacteria in the control sample after incubation for 24 hours (average value)
Mc: 24시간 배양 후 시험 시료의 균수 (평균값)Mc: Number of bacteria in test sample after 24 hours incubation (average value)
그 결과, 락토바실러스 가세리 SWPM102 균주는 식중독의 원인균인 바실러스 세레우스, 충치의 원인균인 스트렙토코쿠스 뮤탄스, 지루성 피부염과 비듬의 원인균인 말라세지아 퍼퍼, 녹농균에 대하여 항균력이 있는 것이 확인되었다(표 7).As a result, it was confirmed that the Lactobacillus gaseri SWPM102 strain had antibacterial activity against Bacillus cereus, a causative agent of food poisoning, Streptococcus mutans, a causative agent of tooth decay, Malassezia puffer, a causative agent of seborrheic dermatitis and dandruff (Pseudomonas aeruginosa). Table 7).
<실험예 7> 억제환 측정Experimental Example 7 Inhibition Ring Measurement
락토바실러스 가세리 SWPM102 균주를 혐기 배양한 50mL 배양액을 10,000 RPM에서 20분간 원심분리 하였다. 원심분리 된 배양액의 상층액(supernatant; sup)만 따라 모아 배양 상층액을 0.2μm 실린지 필터로 여과하였다. 여과한 배양 상층액 35mL을 Evaporator로 수분이 완전히 없어질 때까지 농축하였다. 10배 농축한 배양 상층액에 3.5mL의 멸균 증류수를 넣고 완전히 녹여주었다. 10배 농축한 배양 상층액을 0.2μm 실린지 필터로 여과하였다. 멸균하여 건조해 둔 6mm disc에 10배 농축한 배양 상층액을 20μl loading한 뒤 건조하고, 다시 20μ loading 한 뒤 완전히 건조하였다. mLNA 배지에 각각의 세균을 배양액 100μL를 스프레딩 하였다. 8번의 플레이트에 억제화(disc)를 올렸다. 대조군으로 MRS를 사용하였다. Lock-and-Lock 용기에 멸균한 3차 증류수를 넣고, 15mL tube rack을 넣고, 그 위에 비듬균 말라세지아 퍼퍼(Malassezia furfur)를 스프레딩하여 억제환을 올린 플레이트를 넣어 Lock-and-Lock 용기의 뚜껑을 반만 닫고, 3일 동안 30℃에서 배양하였다. 플레이트를 꺼내 억제환의 지름(inhibition zone)을 측정하였다.50 mL of the anaerobic culture of Lactobacillus gaseri SWPM102 strain was centrifuged at 10,000 RPM for 20 minutes. Only the supernatant (sup) of the centrifuged culture was collected and the culture supernatant was filtered with a 0.2 μm syringe filter. 35 mL of the filtered culture supernatant was concentrated with an evaporator until the water completely disappeared. 3.5 mL of sterile distilled water was added to the culture supernatant concentrated 10 times and completely dissolved. The culture supernatant concentrated 10 times was filtered through a 0.2 μm syringe filter. 20μl of the culture supernatant concentrated 10 times on 6mm disc was sterilized and dried, dried, and 20μ loaded again and completely dried. Spread 100 μL of each culture medium into mLNA medium. Discs were placed on 8 plates. MRS was used as a control. Put sterile tertiary distilled water into the lock-and-lock container, put 15mL tube rack, spread the dandruff malassezia furfur on it, put the plate with the restraint ring on the lock-and-lock container. The lid was half closed and incubated at 30 ° C. for 3 days. The plate was taken out and the inhibition zone (inhibition zone) was measured.
분리된 락토바실러스 가세리 SWPM102 균주의 배양액을 각각의 균주에 대해 억제환 측정(Agar disc assay)을 실시한 결과는 표 8 및 도 3과 같다.Agar disc assay of the isolated culture medium of the isolated Lactobacillus gaseri SWPM102 strain for each strain is shown in Table 8 and FIG.
<실험예 8> 세포독성 평가Experimental Example 8 Cytotoxicity Evaluation
락토바실러스 가세리 SWPM102 균주 배양액의 세포독성 유무를 확인하였다. 인간 각질 형성 세포주인 HaCaT 세포(Invitrogen)를 96웰 플레이트에 2 X 104 cells/well 농도로 부착시키고, FBS를 포함하는 DMEM 배지에서 24시간 배양하였다. PBS(phosphate buffered saline)로 인간 각질 형성 세포를 세척한 후 락토바실러스 가세리 SWPM102 균주 배양액을 농도별(2%, 5%)로 처리하여 24시간 동안 반응시켰다. 그 후, 세포 배양액 100㎕ 당 10㎕의 WST-1 용액을 넣고 30분 내지 2시간 동안 37℃에서 반응시키고 450nm에서 흡광도를 측정하였다. 흡광도는 살아있는 세포 수에 비례하기에 미처리군의 흡광도를 100%로 하였을 때 락토바실러스 가세리 SWPM102 균주 배양액을 농도별로 처리하였을 때의 흡광도를 상대적으로 비교하였다. The cytotoxicity of the Lactobacillus gaseri SWPM102 strain culture was confirmed. HaCaT cells (Invitrogen), a human keratinocyte cell line, were attached to 96-well plates at a concentration of 2 × 10 4 cells / well and incubated in DMEM medium containing FBS for 24 hours. After washing human keratinocytes with PBS (phosphate buffered saline), Lactobacillus gaseri SWPM102 strain cultures were treated by concentration (2%, 5%) and reacted for 24 hours. Thereafter, 10 µl of WST-1 solution was added per 100 µl of the cell culture, and the reaction was performed at 37 ° C. for 30 minutes to 2 hours, and the absorbance was measured at 450 nm. The absorbance was proportional to the number of living cells, so that the absorbance of Lactobacillus gaseri SWPM102 strain culture solution was compared with each other when the absorbance of the untreated group was 100%.
그 결과, 락토바실러스 가세리 SWPM102 균주 배양액은 세포 독성이 없음을 확인하였다(표 9). As a result, it was confirmed that the Lactobacillus gaseri SWPM102 strain culture was not cytotoxic (Table 9).
<실험예 9> 피부 자극성 평가Experimental Example 9 Evaluation of Skin Irritation
락토바실러스 가세리 SWPM102 균주 배양액이 피부에 자극을 일으키는지 여부를 확인하였다. 인간 각질 형성 세포 라인 HaCaT 세포를 96 well cell culture plate에 2 X 104 cells/well 농도로 부착시키고 FBS를 포함하는 DMEM 배지에서 24시간 배양하여 준비하였다. PBS(phosphate buffered saline)로 세포를 세척한 후 DMEM 배지 및 10μM PMA(12-ο-tetradecanoylphorbol-13-acetate) 또는 상기 실험예 2의 락토바실러스 가세리 SWPM102 균주의 희석된 배양액을 20% 농도로 처리하여 세포에서 분비되는 염증성 사이토카인인 IL-1α와 TNF-α의 양을 비교하였다. It was confirmed whether the Lactobacillus gaseri SWPM102 strain culture caused skin irritation. Human keratinocyte cell lines HaCaT cells were attached to 96 well cell culture plates at a concentration of 2 × 10 4 cells / well and prepared by incubating for 24 hours in DMEM medium containing FBS. After washing the cells with PBS (phosphate buffered saline) treated with DMEM medium and 10μM PMA (12-ο-tetradecanoylphorbol-13-acetate) or diluted culture solution of Lactobacillus gasery SWPM102 strain of Experiment 2 at 20% concentration The amount of inflammatory cytokines IL-1α and TNF-α secreted by the cells was compared.
그 결과, 락토바실러스 가세리 SWPM102 균주 배양액은 피부 자극성이 없는 것이 확인되었다(도 4).As a result, it was confirmed that the Lactobacillus gaseri SWPM102 strain culture medium had no skin irritation (FIG. 4).
<실험예 10> 염증 억제 효능 평가Experimental Example 10 Evaluation of Inflammation Inhibitory Effect
락토바실러스 가세리 SWPM102 균주 배양액의 염증 억제 효능을 평가하였다. 인간 각질 형성세포 라인 HaCaT 세포를 96 well cell culture plate에 2 X 104 cells/well 농도로 부착시키고 FBS를 포함하는 DMEM 배지에서 24시간 배양하여 준비하였다. PBS(phosphate buffered saline)로 세포를 세척한 후 DMEM 배지 및 10μM PMA(12-ο-tetradecanoylphorbol-13-acetate)를 처리하여 세포에 염증성 사이토카인의 분비를 유도하였다. 그 후, 락토바실러스 가세리 SWPM102 균주 배양액을 처리하고 염증성 사이토카인의 분비량을 확인 하였다. Inflammatory inhibitory effect of Lactobacillus gaseri SWPM102 strain culture was evaluated. Human keratinocyte cell lines HaCaT cells were attached to 96 well cell culture plates at a concentration of 2 X 10 4 cells / well and prepared by incubating for 24 hours in DMEM medium containing FBS. Cells were washed with PBS (phosphate buffered saline) and treated with DMEM medium and 10 μM PMA (12-ο-tetradecanoylphorbol-13-acetate) to induce secretion of inflammatory cytokines in the cells. Thereafter, the Lactobacillus gaseri SWPM102 strain culture solution was treated and the amount of inflammatory cytokines was confirmed.
그 결과, 락토바실러스 가세리 SWPM102의 배양액을 처리한 군에서 IL-1α의 분비량이 감소하는 것을 확인하였고, 상기 균주 배양액이 염증 억제 효과가 있음을 알 수 있었다(도 5).As a result, it was confirmed that the secretion amount of IL-1α decreased in the group treated with the culture solution of Lactobacillus gasery SWPM102, and it was found that the strain culture solution had an inhibitory effect (FIG. 5).
<실험예 11> 골다공증 치료능 평가Experimental Example 11 Evaluation of Osteoporosis Treatment Capacity
<11-1> 실험 동물<11-1> experimental animal
실험동물은 체중 약 180g의 7주령 래트종 암컷 흰쥐를 사용하였다. 실험동물을 일주일간 적응 시킨 후 8주령 (체중 200~ 205 g)일 때, 난소절제술과 거짓절제술(sham수술)을 실시하였다. 난소 절제군은 난소를 절제한 다음날부터 실험 식이에 따라 군별로 나누어 각 군당 5마리씩 임의배치 시키고, 각각 정상 칼슘 식이 (Normal Ca; Ovx/NCa), 칼슘결핍 식이 (No Ca; Ovx/NCa)를 6주간 급여시켰다. 거짓절제군(Sham군)은 난소적출 과정만 제외한 동일한 과정의 수술을 실시한 후, 정상칼슘 식이 (Sham/NCa)를 급여하여 정상대 조군 (control)으로 하였다. 실험식이와 3차 탈 이온수는 자유 급여법 (ad libitum)으 로 급여하였다. 실험동물들은 1주일마다 일정한 시간에 체중과 식이섭취량을 측정하였다. 실험동물 사육실 환경은 온도 22 ± 2℃, 상대습도 66 ± 5% 로 유지하였고, 명암은 12시간로 조절 하였다.Experimental animals used 7 week old rat female rats weighing about 180 g. At 8 weeks of age (200-205 g), ovarian resection and sham resection (sham surgery) were performed. Ovarian ablation group is divided into groups according to the experimental diet from the day after excision of the ovary 5 randomly placed in each group, respectively, normal calcium diet (Normal Ca; Ovx / NCa), calcium deficiency diet (No Ca; Ovx / NCa) It was paid for six weeks. The sham ablation group (Sham group) underwent the same procedure except for ovarian extraction, and then fed the normal calcium diet (Sham / NCa) to control. The experimental diet and tertiary deionized water were fed by ad libitum. Experimental animals were measured body weight and dietary intake at a certain time every week. The experimental animal breeding environment was maintained at a temperature of 22 ± 2 ℃ and a relative humidity of 66 ± 5%, and the contrast was adjusted to 12 hours.
난소 절제로 인한 에스트로겐 결핍 및 칼슘 켤핍 사료에 의해 유도된 골다공증 동물실험 모델에 하기 표 10과 같이 각 시료를 투여하였다. 이때, 무기질 혼합물로는 칼슘-마그네슘이 풍부한 해조류로부터 추출된 멀티미네랄 보충제 50mg/kg를 투여하였고, 비타민 K2는 2㎍/kg 용량으로 투여하였다. 또한 락토바실러스 살리바리우스 SWPM101 및/또는 락토바실러스 가세리 SWPM102는 미생물의 총 투여량이 1 X 107 CFU/kg가 되도록 투여하였다 (상기 미생물을 2종 투여 시 동량으로 병용 투여하였다).Each sample was administered to an osteoporosis animal test model induced by ovarian ablation and estrogen deficiency and calcium insufficiency feed as shown in Table 10 below. In this case, 50 mg / kg of a multimineral supplement extracted from calcium-magnesium-rich seaweed was administered as a mineral mixture, and vitamin K2 was administered at a dose of 2 µg / kg. In addition, Lactobacillus salivarius SWPM101 and / or Lactobacillus gaseri SWPM102 was administered so that the total dose of microorganisms would be 1 × 10 7 CFU / kg (the same microorganisms were co-administered in two doses).
<11-2> 대퇴골 내 칼슘 및 인 함량 평가<11-2> Evaluation of Calcium and Phosphorus Contents in the Femur
실험 마지막 주에 24시간 동안 사료를 중단 한 후, 대퇴골의 칼슘과 인의 비율, 골강도를 비교하였다. After stopping the feed for 24 hours in the last week of the experiment, the ratio of calcium and phosphorus in the femur and bone strength were compared.
뼈 조직 (대퇴골)의 칼슘과 인의 양을 측정하기 위하여, 뼈 조직을 일정량을 취하여 회화하였다. 구체적으로는, 뼈 조직을 550~600℃의 회화로에서 약 2시간 동안 회화시킨 다음, 식혀서 질산용액 (65% HNO3)을 넣어 재차 회화과정을 거쳐 회분을 측정하였다. 회화된 회분은 6 N HCl에 용해한 후, 0.2% LaCl3 · H2O로 희석하여 원자흡광계 (Atomic Absorption Spectrophotometer)를 이용하여 대퇴골 내 Ca 및 P 양을 422.7 nm에서 측정하였다.In order to measure the amount of calcium and phosphorus in the bone tissue (femur), bone tissue was taken and ingested. Specifically, the bone tissue was incubated for about 2 hours in an induction furnace at 550-600 ° C., cooled, and then nitrate solution (65% HNO 3) was added to ash content. The ashed ash was dissolved in 6 N HCl, diluted with 0.2% LaCl 3 · H 2 O, and the amount of Ca and P in the femur was measured at 422.7 nm using an atomic absorption spectrophotometer.
그 결과, 비타민 K2와 락토바실러스 살리바리우스 SWPM101 및/또는 락토바실러스 가세리 SWPM102를 함께 섭취 시 대퇴골 내 칼슘과 인의 양이 증가하는 것이 확인되었다 (표 11).As a result, when the vitamin K2 and Lactobacillus salivarius SWPM101 and / or Lactobacillus gaseri SWPM102 were taken together, it was confirmed that the amount of calcium and phosphorus in the femur increased (Table 11).
<11-3> 뼈 강도 평가<11-3> bone strength evaluation
실험 동물의 대퇴골의 파단력 (breaking force)을 materials-testing machine을 이용하여 측정하였다. 측정 조건은 하중속도 1 mm/min, 지간거리는 13.9 mm으로 고정하여 수행하였으며, 뼈의 중심 부위에서 일정하게 측정하였다. The breaking force of the femur in the experimental animals was measured using a materials-testing machine. Measurement conditions were carried out by fixing the load speed of 1 mm / min, the distance between the 13.9 mm, was measured at the center of the bone constant.
그 결과, 비타민 K2와 락토바실러스 살리바리우스 SWPM101 및/또는 락토바실러스 가세리 SWPM102를 함께 섭취 시 대퇴골의 파단력이 높은 것이 확인되었다(표 12).As a result, it was confirmed that the fracture force of the femur was high when ingesting vitamin K2 and Lactobacillus salivarius SWPM101 and / or Lactobacillus gaseri SWPM102 together (Table 12).
<11-4> 체중 변화 측정<11-4> Weight change measurement
시료 투여를 개시한 후 6주 동안 정기적으로 1주일마다 한 번씩 체중의 변화를 측정하여 비교 평가하였다. 6주 간의 체중 변화를 그래프로 나타내었고, 6주 검사 후의 체중 값을 측정하였다. After the start of the sample administration, the change in body weight was measured and compared once a week for 6 weeks at regular intervals. The change in body weight over 6 weeks was shown graphically, and the weight value after 6 weeks of testing was measured.
그 결과, 비타민 K2와 락토바실러스 살리바리우스 SWPM101 및/또는 락토바실러스 가세리 SWPM102를 함께 섭취 시 체중이 유의하게 증가하는 것이 확인되었다(도 6, 표 13). As a result, it was confirmed that the body weight is significantly increased when ingesting vitamin K2 and Lactobacillus salivarius SWPM101 and / or Lactobacillus gaseri SWPM102 (Fig. 6, Table 13).
기탁기관명 : 한국생명공학연구원Depositary: Korea Research Institute of Bioscience and Biotechnology
수탁번호 : KCTC13436BPAccession number: KCTC13436BP
수탁일자 : 20171215Deposit Date: 20171215
기탁기관명 : 한국생명공학연구원Depositary: Korea Research Institute of Bioscience and Biotechnology
수탁번호 : KCTC13437BPAccession number: KCTC13437BP
수탁일자 : 20171215Deposit Date: 20171215
<110> Sungwun Pharmacopia Corporation <120> LACTOBACILLUS GASSERI SWPM102 WHICH HAS ANTIFUNGAL ACTIVITY OR ANTIBACTERIAL ACTIVITY <130> KNP180044 <160> 1 <170> KoPatentIn 3.0 <210> 1 <211> 1444 <212> DNA <213> Lactobacillus gasseri <400> 1 tgcagtcgag cgagcttgcc tagatgaatt tggtgcttgc accaaatgaa actagataca 60 agcgagcggc ggacgggtga gtaacacgtg ggtaacctgc ccaagagact gggataacac 120 ctggaaacag atgctaatac cggataacaa cactagacgc atgtctagag tttaaaagat 180 ggttctgcta tcactcttgg atggacctgc ggtgcattag ctagttggta aggcaacggc 240 ttaccaaggc aatgatgcat agccgagttg agagactgat cggccacatt gggactgaga 300 cacggcccaa actcctacgg gaggcagcag tagggaatct tccacaatgg acgcaagtct 360 gatggagcaa cgccgcgtga gtgaagaagg gtttcggctc gtaaagctct gttggtagtg 420 aagaaagata gaggtagtaa ctggccttta tttgacggta attacttaga aagtcacggc 480 taactacgtg ccagcagccg cggtaatacg taggtggcaa gcgttgtccg gatttattgg 540 gcgtaaagcg agtgcaggcg gttcaataag tctgatgtga aagccttcgg ctcaaccgga 600 gaattgcatc agaaactgct gaacttgagt gcagaagagg agagtggaac tccatgtgta 660 gcggtggaat gcgtagatat atggaagaac accagtggcg aaggcggctc tctggtctgc 720 aactgacgct gaggctcgaa agcatgggta gcgaacagga ttagataccc tggtagtcca 780 tgccgtaaac gatgagtgct aagtgttggg aggtttccgc ctctcagtgc tgcagctaac 840 gcattaagca ctccgcctgg ggagtacgac cgcaaggttg aaactcaaag gaattgacgg 900 gggcccgcac aagcggtgga gcatgtggtt taattcgaag caacgcgaag aaccttacca 960 ggtcttgaca tccagtgcaa acctaagaga ttaggagttc ccttcgggga cgctgagaca 1020 ggtggtgcat ggctgtcgtc agctcgtgtc gtgagatgtt gggttaagtc ccgcaacgag 1080 cgcaaccctt gtcattagtt gccatcatta agttgggcac tctaatgaga ctgccggtga 1140 caaaccggag gaaggtgggg atgacgtcaa gtcatcatgc cccttatgac ctgggctaca 1200 cacgtgctac aatggacggt acaacgagaa gcgaacctgc gaaggcaagc ggatctctga 1260 aagccgttct cagttcggac tgtaggctgc aactcgccta cacgaagctg gaatcgctag 1320 taatcgcgga tcagcacgcc gcggtgaata cgttcccggg ccttgtacac accgcccgtc 1380 acaccatgag agtctgtaac acccaaagcc ggtgggataa cctttatagg agtcagccgt 1440 ctaa 1444 <110> Sungwun Pharmacopia Corporation <120> LACTOBACILLUS GASSERI SWPM102 WHICH HAS ANTIFUNGAL ACTIVITY OR ANTIBACTERIAL ACTIVITY <130> KNP180044 <160> 1 <170> KoPatentIn 3.0 <210> 1 <211> 1444 <212> DNA <213> Lactobacillus gasseri <400> 1 tgcagtcgag cgagcttgcc tagatgaatt tggtgcttgc accaaatgaa actagataca 60 agcgagcggc ggacgggtga gtaacacgtg ggtaacctgc ccaagagact gggataacac 120 ctggaaacag atgctaatac cggataacaa cactagacgc atgtctagag tttaaaagat 180 ggttctgcta tcactcttgg atggacctgc ggtgcattag ctagttggta aggcaacggc 240 ttaccaaggc aatgatgcat agccgagttg agagactgat cggccacatt gggactgaga 300 cacggcccaa actcctacgg gaggcagcag tagggaatct tccacaatgg acgcaagtct 360 gatggagcaa cgccgcgtga gtgaagaagg gtttcggctc gtaaagctct gttggtagtg 420 aagaaagata gaggtagtaa ctggccttta tttgacggta attacttaga aagtcacggc 480 taactacgtg ccagcagccg cggtaatacg taggtggcaa gcgttgtccg gatttattgg 540 gcgtaaagcg agtgcaggcg gttcaataag tctgatgtga aagccttcgg ctcaaccgga 600 gaattgcatc agaaactgct gaacttgagt gcagaagagg agagtggaac tccatgtgta 660 gcggtggaat gcgtagatat atggaagaac accagtggcg aaggcggctc tctggtctgc 720 aactgacgct gaggctcgaa agcatgggta gcgaacagga ttagataccc tggtagtcca 780 tgccgtaaac gatgagtgct aagtgttggg aggtttccgc ctctcagtgc tgcagctaac 840 gcattaagca ctccgcctgg ggagtacgac cgcaaggttg aaactcaaag gaattgacgg 900 gggcccgcac aagcggtgga gcatgtggtt taattcgaag caacgcgaag aaccttacca 960 ggtcttgaca tccagtgcaa acctaagaga ttaggagttc ccttcgggga cgctgagaca 1020 ggtggtgcat ggctgtcgtc agctcgtgtc gtgagatgtt gggttaagtc ccgcaacgag 1080 cgcaaccctt gtcattagtt gccatcatta agttgggcac tctaatgaga ctgccggtga 1140 caaaccggag gaaggtgggg atgacgtcaa gtcatcatgc cccttatgac ctgggctaca 1200 cacgtgctac aatggacggt acaacgagaa gcgaacctgc gaaggcaagc ggatctctga 1260 aagccgttct cagttcggac tgtaggctgc aactcgccta cacgaagctg gaatcgctag 1320 taatcgcgga tcagcacgcc gcggtgaata cgttcccggg ccttgtacac accgcccgtc 1380 acaccatgag agtctgtaac acccaaagcc ggtgggataa cctttatagg agtcagccgt 1440 ctaa 1444
Claims (15)
Lactobacillus gasseri SWPM102 having antifungal activity against Malassezia furfur (Accession No .: KCTC13437BP).
상기 락토바실러스 가세리 SWPM102는 바실러스 세레우스(Bacillus cereus), 스트렙토코쿠스 뮤탄스(Streptococcus mutans) 및 녹농균(Pseudomonas aeruginosa)으로 구성되는 군으로부터 선택되는 하나 이상에 대하여 항균 활성 또는 항진균 활성을 갖는 것을 특징으로 하는 락토바실러스 가세리 SWPM102.
The method of claim 1,
The Lactobacillus gaseri SWPM102 has antimicrobial activity or antifungal activity against at least one selected from the group consisting of Bacillus cereus, Streptococcus mutans, and Pseudomonas aeruginosa. Lactobacillus gastery SWPM102.
상기 락토바실러스 가세리 SWPM102는 pH3의 조건 하 증식능을 갖는 것을 특징으로 하는 락토바실러스 가세리 SWPM102.
The method of claim 1,
The Lactobacillus fern SWPM102 is characterized in that it has a proliferative capacity under the condition of pH3.
상기 락토바실러스 가세리 SWPM102는 pH6.8의 조건 하 증식능을 갖는 것을 특징으로 하는 락토바실러스 가세리 SWPM102.
The method of claim 1,
The Lactobacillus gaseous SWPM102 is characterized in that it has a proliferative capacity under the conditions of pH6.8.
상기 락토바실러스 가세리 SWPM102는 0.3 중량% 담즙산을 포함하는 배지 조건 하 증식능을 갖는 것을 특징으로 하는 락토바실러스 가세리 SWPM102.
The method of claim 1,
The Lactobacillus gasteria SWPM102 is characterized in that it has a proliferative capacity under medium conditions containing 0.3% by weight bile acid.
상기 락토바실러스 가세리 SWPM102는 과산화수소 생성능이 있는 것을 특징으로 하는 락토바실러스 가세리 SWPM102.
The method of claim 1,
The Lactobacillus gaseous SWPM102 is characterized in that the ability to produce hydrogen peroxide Lactobacillus gaseous SWPM102.
The Lactobacillus fern SWPM102 of claim 1, the culture or extract thereof, and selected from the group consisting of Bacillus cereus, Streptococcus mutans and Pseudomonas aeruginosa. Antimicrobial composition having antibacterial activity against the above bacteria.
An antifungal composition comprising the Lactobacillus fern SWPM102 of claim 1, a culture thereof or an extract thereof, and having antifungal activity against Malassezia furfur.
Lactobacillus gaseous SWPM102 of claim 1, a cosmetic composition comprising the culture or extract thereof.
Claim 1, comprising the Lactobacillus gaseous SWPM102, its culture or its extract, food poisoning, seborrheic dermatitis, dandruff, respiratory disease due to Pseudomonas aeruginosa infection, pneumonia and caries caused by Pseudomonas aeruginosa infection A pharmaceutical composition for preventing or treating at least one disease selected from the group consisting of:
A food composition comprising the Lactobacillus scavenger SWPM102 of claim 1, its culture, or its extract.
Claim 1 Lactobacillus gaseous SWPM102, comprising the culture or extract thereof, anti-inflammatory pharmaceutical composition.
Feed composition comprising the Lactobacillus gaseous SWPM102 of claim 1, its culture or its extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180109248A KR102063554B1 (en) | 2018-09-12 | 2018-09-12 | Lactobacillus gasseri swpm102 which has antifungal activity or antibacterial activity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180109248A KR102063554B1 (en) | 2018-09-12 | 2018-09-12 | Lactobacillus gasseri swpm102 which has antifungal activity or antibacterial activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR102063554B1 true KR102063554B1 (en) | 2020-01-09 |
Family
ID=69154752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020180109248A KR102063554B1 (en) | 2018-09-12 | 2018-09-12 | Lactobacillus gasseri swpm102 which has antifungal activity or antibacterial activity |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102063554B1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102198553B1 (en) * | 2020-06-09 | 2021-01-05 | 주식회사 비피도 | Composition improving, preventing or treating halitosis or dental caries comprising Lactobacillus gasseri HHuMIN D derived from human oral cavity |
| KR102269965B1 (en) * | 2020-12-31 | 2021-06-28 | 주식회사 바이오뱅크힐링 | Lactobacillus paragasseri strain, and vesicles from thereof and anti-inflammation and anti-bacteria uses of thereof |
| KR102296289B1 (en) | 2020-12-31 | 2021-09-01 | 주식회사 바이오뱅크힐링 | Lactobacillus gasseri strain, and vesicles from thereof and anti-inflammation and anti-bacteria uses of thereof |
| US11285183B2 (en) | 2018-05-23 | 2022-03-29 | Kobiolabs, Inc. | Lactobacillus gasseri KBL697 strain and use thereof |
| KR102554125B1 (en) * | 2022-10-24 | 2023-07-13 | (주)헥토헬스케어 | Lactobacillus gasseri BELG08 preventive or ameliorating effect on vaginitis and composition comprising the same |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100712286B1 (en) | 1999-06-21 | 2007-04-27 | 악티알 파마수티카 엘디에이. | Combination of lactic acid bacteria and its use for the prevention and/or treatment of infections and inflammatory conditions |
| KR101108428B1 (en) | 2006-08-04 | 2012-01-31 | (주)바이오니아 | Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation |
-
2018
- 2018-09-12 KR KR1020180109248A patent/KR102063554B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100712286B1 (en) | 1999-06-21 | 2007-04-27 | 악티알 파마수티카 엘디에이. | Combination of lactic acid bacteria and its use for the prevention and/or treatment of infections and inflammatory conditions |
| KR101108428B1 (en) | 2006-08-04 | 2012-01-31 | (주)바이오니아 | Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11285183B2 (en) | 2018-05-23 | 2022-03-29 | Kobiolabs, Inc. | Lactobacillus gasseri KBL697 strain and use thereof |
| US11819526B2 (en) | 2018-05-23 | 2023-11-21 | Kobiolabs, Inc. | Lactobacillus Gasseri KBL697 strain and use thereof |
| KR102198553B1 (en) * | 2020-06-09 | 2021-01-05 | 주식회사 비피도 | Composition improving, preventing or treating halitosis or dental caries comprising Lactobacillus gasseri HHuMIN D derived from human oral cavity |
| KR102269965B1 (en) * | 2020-12-31 | 2021-06-28 | 주식회사 바이오뱅크힐링 | Lactobacillus paragasseri strain, and vesicles from thereof and anti-inflammation and anti-bacteria uses of thereof |
| KR102296289B1 (en) | 2020-12-31 | 2021-09-01 | 주식회사 바이오뱅크힐링 | Lactobacillus gasseri strain, and vesicles from thereof and anti-inflammation and anti-bacteria uses of thereof |
| KR102554125B1 (en) * | 2022-10-24 | 2023-07-13 | (주)헥토헬스케어 | Lactobacillus gasseri BELG08 preventive or ameliorating effect on vaginitis and composition comprising the same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102063554B1 (en) | Lactobacillus gasseri swpm102 which has antifungal activity or antibacterial activity | |
| JP5718917B2 (en) | Novel Lactobacillus plantarum and composition containing the same | |
| KR101750468B1 (en) | Composition comprising Lactobacillus fermentum MG901 or Lactobacillus plantarum MG989 | |
| DE69831578T2 (en) | LACTOBACILLUS CASEI RHAMNOSUS-CONTAINING PHARMACEUTICAL FORMULATION | |
| US6849256B1 (en) | Inhibition of pathogens by probiotic bacteria | |
| CA2602108C (en) | Skin treatment compositions | |
| KR101869275B1 (en) | Novel Calidifontibacter sp. R161 having anti-bacterial, anti-oxidant, skin-whitening and anti-wrinkle effect | |
| US20110117068A1 (en) | Probiotic microorganisms for the reduction of manure odor | |
| KR101287126B1 (en) | Pharmaceutical compositon prevention and treatment of vaginitis and urinary tract infection comprising fermented solution of plant-originated Lactic acid bacteria | |
| KR101937758B1 (en) | Lactobacillus fermentum UBC-U32, and use thereof in prevention and treatment of neurodegenerative disease | |
| AU2004267383A1 (en) | Bacterial strains, compositions including same and probiotic use thereof | |
| WO2014193014A1 (en) | Nano-sized kimchi lactic acid bacteria | |
| KR102063544B1 (en) | Lactobacillus salivarius swpm101 which has antifungal activity or antibacterial activity | |
| KR100996056B1 (en) | Lactobacillus brevis HY7401 having protective effect against colitis and products containing thereof as effective component | |
| KR102164906B1 (en) | A composition for preventing improving or treating bone disease comprising lactobacillus salivarius swpm101 and lactobacillus gasseri swpm102 | |
| EP1229923A1 (en) | Inhibition of pathogens by bacillus coagulans strains | |
| KR101406168B1 (en) | Novel lactobacillus plantarum and compositions comprising the same | |
| KR102207512B1 (en) | Lactobacillus jensenii swpm104 which has antibacterial activity | |
| KR102421144B1 (en) | Bifidobacterium bifidum EPS DA-LAIM promoting the growth of lactobacillus and polysaccharide therefrom | |
| KR101355441B1 (en) | Lactobacillus johnsonii HY7042 helpful to maintain healthy vaginal environment and products containing thereof as effective component | |
| KR102491640B1 (en) | Weissella cibaria strain for suppressing dental caries inducing bacteria and use thereof | |
| KR102229090B1 (en) | A composition for preventing, improving or treating ischemic brain disease | |
| KR20220092787A (en) | A novel Lactobacillus paracasei strain and uses thereof | |
| KR20190006285A (en) | Antibacterial composition comprising an extract of schisandra chinesis | |
| KR20220109667A (en) | Lactobacillus plantarum having inhibitory effect on osteoclast differentiation and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AMND | Amendment | ||
| X091 | Application refused [patent] | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant |